AUTHORS
Ehab Atallah, MD, David Andorsky, MD2, Marlise Rachael Luskin, MD, MSCE3, Srinivas Tantravahi, MD4, Koji Sasaki, MD, PhD5, James P. Dugan, MD6, CelesteAnn Bremer, MD7, Vivian Oehler, MD8, Joshua F. Zeidner, MD9, Moshe Levy, MD10, Camille Abboud, MD11, Paul Koller, MD12, Bonnie Kiner-Strachan13, Habte Yimer, MD14, Caitlin Cohen, ANP15, Dramane Laine, PhD16, John (randy) Sabo, MPH17, Ennan Gu18, Andrea Damon, PhD19, Michael Mauro, MD20, Jorge Cortes, MD21
AFFILIATIONS
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, Boulder, Colorado, United States
3 Dana-Faber Cancer Institute, Boston, Massachusetts, United States
4 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
5 Current Affiliation: Department of Laboratory Medicine, Institute of Science Tokyo, Tokyo, Japan, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 Novant Health Cancer Institute, Winston-Salem, North Carolina, United States
7 Virginia Oncology Associates, Virginia Beach, Virginia, United States
8 Fred Hutchinson Cancer Centre, Seattle, Washington, United States
9 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, United States
10 Baylor Scott and White Health, Dallas, Texas, United States
11 Washington University School of Medicine, St Louis, Missouri, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 Current Affiliation: Westchester Medical Center, Valhalla, New York, United States, Perlmutter Cancer Center, NYU Langone, New York, New York, United States
14 Christus Trinity Mother Frances Hospital Texas Oncology, Tyler, Texas, United States, Current Affiliation: Texas Oncology, Sarah Cannon Research Institute, Tyler, Texas, United States
15 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
16 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
17 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
18 Novartis Pharmaceutical Company, Cambridge, Massachusetts, United States
19 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Current Affiliation: Division of Hematology and Oncology, University of Alabama, Birmingham, Alabama, United States, Georgia Cancer Center at August University, Augusta, Georgia, United States
ABSTRACT
Introduction
ASC is approved in the US for newly diagnosed and previously treated CML-CP. ASC2ESCALATE (NCT05384587) evaluates ASC with response-based dose escalation in first-line (1L) and second-line (2L) CML-CP. In the wk 48 analysis of the 2L cohort (cutoff: August 13, 2025), 82.2% of pts had BCR::ABL1IS ≤1% at wk 24; the primary endpoint was met with a major molecular response (MMR) rate of 59.4% at wk 48. We report updated safety (n=101) and wk 96 efficacy (n=74) results in the 2L cohort in ASC2ESCALATE (cutoff: April 16, 2026).
Methods
ASC2ESCALATE is a US, single-arm, open-label trial of ASC in 1L or 2L CML-CP without the T315I mutation, with dose escalation based on ELN2020 optimal response milestones at 6 and 12 mo.
All pts started treatment (Tx) with ASC 80 mg once daily (QD). Pts with BCR::ABL1IS >1% at wk 24 could dose escalate to 200 mg QD. Pts with BCR::ABL1IS >0.1% at wk 48 could dose escalate from 80 to 200 mg QD or from 200 mg QD to 200 mg twice daily (BID) or come off study. In pts with Tx toxicity, dose escalation was not allowed, and the same dose of ASC was continued.
Results
This IA included all 101 pts with 2L CML-CP. Prior Txs were imatinib (41.6%) and second-generation TKIs (dasatinib [44.6%], nilotinib [9.9%], and bosutinib [5.0%]); pts discontinued due to lack of efficacy (56.4%), intolerance (42.6%), and study enrollment (1.0%). Most pts received prior Tx for ≥12 mo (64.4%). Baseline BCR::ABL1IS levels were >0.1% to 1% (39.6%), >1% to 10% (30.7%), and >10% (29.7%). Important medical history included hypertension in 47.5% of pts. At cutoff, 74 pts (73.3%) remained on ASC and 1 (1.0%) completed study Tx; pts discontinued due to adverse events (AEs; 9.9%), pt decision (6.9%), unsatisfactory therapeutic effect (4.0%), physician decision (3.0%), loss to follow-up (2.0%). After study Tx discontinuation (due to AEs [n=1] and due to pt decision [n=3]), 4 pts continued to receive ASC off study. Relative dose intensity was >90% to 100% in 76.2% of pts; median dose intensity was 80.0 (range, 28-277) mg/day. Median duration of ASC exposure was 97.1 (range, 6-157) wk. Of 101 pts, dose escalation from 80 to 200 mg QD occurred in 21 (20.8%; wk 24 [n=4]; 48 [n=17]); 3 of 4 pts with dose escalation to 200 mg QD at wk 24 escalated to 200 mg BID at wk 48.
Pts evaluable for all efficacy analyses at wk 48 (n=101) and 96 (n=74) completed assessments for the respective time point or discontinued earlier. At wk 48, 61 pts (60.4%) achieved MMR; response was confirmed in 1 pt after the wk 48 data cutoff. Of these 61 pts, 21 had not yet reached the wk 96 assessment. At wk 96, 51 pts (68.9%) had BCR::ABL1IS ≤1%, and 38 (51.4%) had MMR; the MMR rate was similar in pts who discontinued prior Tx due to intolerance (16/32 [50.0%]) vs lack of efficacy (22/42 [52.4%]). Median time to MMR was 23.1 (95% CI, 13.1-27.1) wk. Deep molecular responses at wk 96 included MR4 (19 [25.7%]) and MR4.5 (13 [17.6%]). Of pts with dose escalation (wk 24, n=1; wk 24 and 48, n=2; wk 48, n=12) evaluable for efficacy, BCR::ABL1IS levels at wk 96 included >10% (n=1, n=0, n=0), >1% to ≤10% (n=0, n=1, n=0), >0.1% to ≤1% (n=0, n=1, n=10), and ≤0.1% (n=0, n=0, n=2).
Most common (≥20%) all-grade AEs were headache (30.7%), nausea (30.7%), fatigue (24.8%), diarrhea (23.8%), vomiting (22.8%), cough (22.8%), arthralgia (21.8%), and hypertension (21.8%). Most AEs were grade 1/2. Grade ≥3 AEs (≥5%) were hypertension (13.9%), thrombocytopenia (6.9%), neutropenia (6.9%), and syncope (5.0%). AEs led to dose adjustment/interruption in 43 pts (42.6%). Discontinuation due to AEs occurred in 10 pts (9.9%); 2 of these occurred after the wk 48 analysis cutoff (1 each due to nausea and increased lipase). Arterial occlusive events occurred in 5 pts (5.0%); none led to dose reduction or discontinuation, and most events resolved or were resolving by the data cutoff. Following dose escalation, most new or worsening AEs were grade 1/2. No on-Tx deaths or disease progression occurred.
Conclusions
In this IA, ASC continued to demonstrate high molecular response rates in 2L and a safety and tolerability profile consistent with previous ASC data. No new or worsening safety signals were observed. Few AEs led to discontinuation. These IA results after additional exposure continue to support ASC as a Tx option in 2L CML-CP. The impact of dose escalation continues to be explored. The wk 96 analysis, including safety and efficacy results in all 101 pts, will be presented at ASH 2026.
DISCLOSURES
Ehab Atallah, MD: Strong and Hanni - Honoraria; BMS - Honoraria; AbbVie - Honoraria; Syndax - Honoraria; Novartis - Research Funding; Xencor - Research Funding; Amgen - Research Funding; UpToDate - Patents & Royalties; Strong and Hanni - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Inhibikinase - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)